NCT02756858View on ClinicalTrials.gov

An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Alzheimer's Disease
Interventions
DRUG

ANAVEX2-73

Trial Locations (5)

3050

Melbourne Health - The Royal Melbourne Hospital, Melbourne

3084

Austin Health - Heidelberg Repatriation Hospital, Melbourne

3162

Caulfield Hospital, Melbourne

Unknown

Nucleus Network- Centre for Clinical Studies, Melbourne

St. Vincent's Hospital, Melbourne

Sponsors
All Listed Sponsors
lead

Anavex Life Sciences Corp.

INDUSTRY